Skip to main content

Peer Review reports

From: Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial

Original Submission
24 Jul 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
26 Aug 2022 Reviewed Reviewer Report - Mohammadreza Shalbafan
17 Nov 2022 Reviewed Reviewer Report
27 Nov 2022 Reviewed Reviewer Report - Nikita A Nekliudov
4 Dec 2022 Author responded Author comments - Alireza Ranjbar Naeini
Resubmission - Version 4
4 Dec 2022 Submitted Manuscript version 4
9 Dec 2022 Author responded Author comments - Alireza Ranjbar Naeini
Resubmission - Version 5
9 Dec 2022 Submitted Manuscript version 5
16 Dec 2022 Reviewed Reviewer Report - Mohammadreza Shalbafan
1 Jan 2023 Reviewed Reviewer Report
6 Jan 2023 Author responded Author comments - Alireza Ranjbar Naeini
Resubmission - Version 6
6 Jan 2023 Submitted Manuscript version 6
1 Feb 2023 Reviewed Reviewer Report
7 Mar 2023 Author responded Author comments - Alireza Ranjbar Naeini
Resubmission - Version 7
7 Mar 2023 Submitted Manuscript version 7
Publishing
17 Mar 2023 Editorially accepted
31 Mar 2023 Article published 10.1186/s12879-023-08172-5

You can find further information about peer review here.

Back to article page